Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 1997

Primary Completion Date

June 30, 2002

Conditions
Melanoma
Interventions
BIOLOGICAL

dendritic cell-MART-1 peptide vaccine

Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.

PROCEDURE

leukapheresis

Patients require a single leukapheresis to obtain 2x10\^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00005617 - Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma | Biotech Hunter | Biotech Hunter